Reata Pharmaceuticals Closes IPO


IRVING, Texas, June 01, 2016 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced the completion of its initial public offering of 6,325,000 shares of its Class A common stock at $11.00 per share, which includes the exercise in full by the underwriters of their over-allotment option. The shares of Class A common stock began trading on The NASDAQ Global Market on May 26, 2016, under the ticker symbol “RETA.”

About Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases. Reata focuses on drugs with novel mechanisms of action that modulate important regulatory proteins, called transcription factors, that coordinate the cellular response to stressors by activating or suppressing the activity of many target proteins.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.